Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com.

FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc.

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.

Analysts have provided the following ratings for Cytek Biosciences (NASDAQ:CTKB) within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for Cytek Biosciences.

Cytek Biosciences (NASDAQ:CTKB) reported fourth-quarter and full-year 2025 results on Wednesday, describing a return to growth in the back half of the year amid what management characterized as a ...

Cytek Biosciences Inc. research and ratings by Barron's. View CTKB revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Interested parties may access live and archived webcasts of the presentations for the Stephens and Piper Sandler events referenced above on the “Investors” section of the company website at: investors ...

Cytek Biosciences, Inc. announced that it will report its financial results for the fourth quarter and full year 2024 on February 27, 2025, after market close. A conference call to discuss these ...

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell ...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...

Cytek focuses on cell analysis primarily for research purposes. The company joined the S&P SmallCap 600 Index last month. Cytek lowered its revenue forecast for 2023. Cytek, which joined the S&P 600 ...